{
    "nctId": "NCT00166543",
    "briefTitle": "Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer",
    "officialTitle": "A Phase II, Randomized, Double-Blinded Efficacy and Safety Study of Three Doses of TAS-108 Administered Orally in Postmenopausal Patients With Locally Advanced or Locally Recurrent Inoperable or Progressive Metastatic Breast Cancer Following Standard First-Line Endocrine Therapy",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 146,
    "primaryOutcomeMeasure": "To evaluate the safety of TAS-108 administered on this schedule",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal females\n* Histologically or cytologically confirmed diagnosis of breast carcinoma\n* Locally advanced or locally recurrent inoperable or metastatic breast carcinoma with documented disease progression\n* Has laboratory documentation of positive estrogen receptor (ER) and/or progesterone receptor (PgR) status, and has responded to the standard first or second line hormonal anti-tumor therapy given\n* Has received and whose disease progressed after one or two prior systemic hormonal anti-tumor therapies\n* Performance status of greater than or equal to 2 on the Zubrod scale\n* Predicted life expectancy of greater than or equal to 12 weeks\n* Must give written informed consent\n* Measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria\n* Absolute granulocyte count of greater than 1,500/meqL, platelet count greater than 75,000/meqL, and a hemoglobin of greater than 10 g/dL\n* Adequate liver and renal function as defined by a bilirubin of less than 1.5 times the upper limit of normal and a creatinine of less than 1.5 times the upper limit of normal\n* Transaminases must be less than 2.5 times the upper limit of normal except for patients with liver metastases who may have transaminases less than 5 times the upper limit of normal.\n* The patient has recovered from all previous anti-cancer treatment related to toxicities to at least Grade 1.\n* All previous investigational drugs must be stopped at least four weeks before commencement of treatment with TAS-108.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}